These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series. Naidoo J; O'Toole D; Kennedy MJ; Reynolds JV; O'Connor M; O'Byrne K Ir J Med Sci; 2012 Jun; 181(2):211-4. PubMed ID: 22048868 [TBL] [Abstract][Full Text] [Related]
5. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Sun W; Lipsitz S; Catalano P; Mailliard JA; Haller DG; J Clin Oncol; 2005 Aug; 23(22):4897-904. PubMed ID: 16051944 [TBL] [Abstract][Full Text] [Related]
6. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. Dousset B; Saint-Marc O; Pitre J; Soubrane O; Houssin D; Chapuis Y World J Surg; 1996 Sep; 20(7):908-14; discussion 914-5. PubMed ID: 8678970 [TBL] [Abstract][Full Text] [Related]
7. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542 [TBL] [Abstract][Full Text] [Related]
8. Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors. Schrader J; Henes FO; Blaeker M; Zimmermann-Fraedrich K; Pace A; Perez D; Izbicki JR; Lohse AW; Benten D Endocrine; 2019 Aug; 65(2):460-467. PubMed ID: 31037707 [TBL] [Abstract][Full Text] [Related]
9. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. Engstrom PF; Lavin PT; Moertel CG; Folsch E; Douglass HO J Clin Oncol; 1984 Nov; 2(11):1255-9. PubMed ID: 6238136 [TBL] [Abstract][Full Text] [Related]
10. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). Castellano D; Capdevila J; Sastre J; Alonso V; Llanos M; García-Carbonero R; Manzano Mozo JL; Sevilla I; Durán I; Salazar R Eur J Cancer; 2013 Dec; 49(18):3780-7. PubMed ID: 24012098 [TBL] [Abstract][Full Text] [Related]
11. Everolimus for advanced pancreatic neuroendocrine tumors. Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K; N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238 [TBL] [Abstract][Full Text] [Related]
12. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. Raymond E; Dahan L; Raoul JL; Bang YJ; Borbath I; Lombard-Bohas C; Valle J; Metrakos P; Smith D; Vinik A; Chen JS; Hörsch D; Hammel P; Wiedenmann B; Van Cutsem E; Patyna S; Lu DR; Blanckmeister C; Chao R; Ruszniewski P N Engl J Med; 2011 Feb; 364(6):501-13. PubMed ID: 21306237 [TBL] [Abstract][Full Text] [Related]